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The diagnostic and prognostic criteria of acute-on-chronic liver failure (ACLF) were developed in 
patients with no Hepatitis B virus (HBV) cirrhosis (CANONIC study). The aims of this study were to 
evaluate whether the diagnostic (CLIF-C organ failure score; CLIF-C OFs) criteria can be used to classify 
patients; and the prognostic score (CLIF-C ACLF score) could be used to provide prognostic information 
in HBV cirrhotic patients with ACLF. 890 HBV associated cirrhotic patients with acute decompensation 
(AD) were enrolled. Using the CLIF-C OFs, 33.7% (300 patients) were diagnosed as ACLF. ACLF was more 
common in the younger patients and in those with no previous history of decompensation. The most 
common organ failures were ‘hepatic’ and ‘coagulation’. As in the CANONIC study, 90-day mortality 
was extremely low in the non-ACLF patients compared with ACLF patients (4.6% vs 50%, p < 0.0001). 
ACLF grade and white cell count, were independent predictors of mortality. CLIF-C ACLFs accurately 
predicted short-term mortality, significantly better than the MELDs and a disease specific score 
generated for the HBV patients. Current study indicates that ACLF is a clinically and pathophysiology 
distinct even in HBV patients. Consequently, diagnostic criteria, prognostic scores and probably the 
management of ACLF should base on similar principles.
Acute on chronic liver failure (ACLF) is a dynamic syndrome observed in the hospitalized cirrhotic patients 
either with or without an identified precipitating factor characterized by hepatic and or extrahepatic organ fail-
ures and high mortality1. The elements of the above working definition was proposed by a working group under 
the auspices of the European and the America association for the study of liver (European Association for the 
Study of the Liver/the America association for the study of liver Disease, EASL/AASLD) in 20102. Since then, 
large prospective studies were performed by the EASL chronic liver failure (CLIF) Consortium, the data from 
which suggested that the diagnosis of ACLF can be accurately made using the CLIF-Consortium Organ Failure 
score (CLIF-C OFs; CLIF Acute-on Chronic Liver Failure in cirrhosis (CANONIC) study) and its prognosis 
determined using the CLIF-Consortium acute-on chronic liver failure score (CLIF-C ACLFs)3,4. In patients with 
acute decompensation4 (AD, refers to the acute development within 1-month before admission of ascites, variceal 
hemorrhage, hepatic encephalopathy and/or bacterial infections) who did not fulfill criteria for the diagnosis of 
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ACLF, the CLIF acute decompensation score (CLIF-Consortium acute decompensation score, CLIF-C ADs) was 
validated to provide prognostic information5. The North American Consortium for the Study of End Stage Liver 
Disease (NACSELD), made similar observations confirming high mortality rates of patients with organ failures 
in the hospitalized cirrhotic patients with bacterial infection6.
One of the limitations of the CLIF consortium classification is that it has only been validated in cohorts of 
patients from Europe and the patient populations studied had an extremely low prevalence of HBV infection, 
which is the commonest cause of chronic liver disease in the Eastern Pacific rim. Given that infection with HBV 
may be associated with disease flares, which can lead to rapid deterioration in liver function despite introduc-
tion of effective antiviral therapy, it is unclear whether criteria developed for non-HBV induced ACLF can also 
be applied to patients with HBV related ACLF. A Consensus definition has of necessity been developed under 
the auspices of the Asia Pacific association for the Study of liver disease for the definition of ACLF, which is 
however, based on expert opinion, rather than prospectively validated data. The definition proposed by the 
Asia-Pacific association for the study of liver Disease (APASL) was “acute hepatic insult manifesting as jaundice 
and coagulopathy, complicated within four weeks by ascites and/or encephalopathy in a patient with previously 
diagnosed or undiagnosed chronic liver disease7”. As is self evident, the proposed definitions are very different8. 
Therefore, a World Consensus on the definition of ACLF was organized under the auspices of the World Congress 
of Gastroenterology, which amongst other recommendations concluded that the CLIF criteria should be validated 
in an Asian population that included patients with HBV infection9.
Therefore, the aims of this study was to evaluate whether the CLIF-C OF score can be used to classify patients 
presenting with HBV infection and AD into an ACLF and no ACLF groups with distinct clinical characteristics 
and outcomes. We then determined whether the CLIF-C ACLF and the CLIF-C AD scores provide prognostic 
information in these two patient groups in comparison with standard prognostic scores. The study also aimed to 
develop a HBV specific score and compare its performance with the CLIF scores. In order to achieve these aims, 
the EASL CLIF Consortium set up collaboration with Ren Ji Hospital, Shanghai, China and all the data were ana-
lyzed by the Data Management Centre of the EASL CLIF Consortium in a manner similar to that performed for 
the CANONIC study4 to allow direct comparison.
Results
Clinical characteristics of the patients at the time of hospital admission. The flow chart for both 
screening and enrollment of patients was presented at Fig. 1. There were 3004 hospitalized cirrhotic patients 
Figure 1. Screening, enrollment, and flow of patients according to the presence or absence of ACLF 
according to CLIF-C OF score. 
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screened in a single tertiary hospital (Ren Ji Hospital) in Shanghai from January 2005 to December 2010 and 890 
HBV associated cirrhotic patients with AD were enrolled. Clinical characteristics of enrolled patients are sum-
marized in Supplementary table S1. The mean age in the current series was 50 years and most patients (76.7%) 
were male. Seven-hundred and thirty-three patients (82.4%) presented significant HBV replication (HBV-
DNA > 100 IU/ml) in concordance to the low percentage of patients (23.5%) treated with nucleotide analogs 
(NUCs) within 6 months prior hospitalization. Most patients had received lamivudine and none had been treated 
with tenofovir (a NUC with a high barrier to resistance). In 274 patients, NUCs were started after hospital admis-
sion with AD. Prior history of AD was present in only 55.1% of patients. In the vast majority of patients (90.7%) 
no other cause for cirrhosis other than chronic HBV was found. In the remainder patients HBV infection was 
associated with alcoholism (6.2%), schistosomiasis (1.2%) and other hepatic viruses (1.9%; HCV 0.8%, HEV 0.8% 
and CMV 0.7%).
The main indication for hospital admission was ascites (56.9%) followed by GI-bleeding (26.5%), hepatic 
encephalopathy (11.8%) and bacterial infections (4.4%). Potential precipitating events of acute decompensation 
were present in 54.8% (488/890) patients. The most frequent precipitating event (PE) was bacterial infection 
(10.6%), followed by GI-bleeding and active alcoholism (7.5% and 7.2%, respectively). HBV reactivation was 
observed in only 41 patients (4.6%). In 7 patients, this was related to sudden cessation of anti-viral therapy. No 
cases of de novo reactivation were observed. Only 99 patients (11.1%) presented more than one PE.
Three hundred and eighty patients (42.7%) presented at least one OF. The most frequent OF was hepatic 
failure, which was present in 30.1% of the patients followed by coagulation failure (26.1%), renal failure (10.0%), 
cerebral failure (5.2%), circulatory failure (2.4%) and respiratory failure (1.2%). Renal and cerebral dysfunctions 
were present in 5.3% and 8.3% of patients, respectively. Mean model for end-stage liver disease (MELD) and 
MELD-Sodium (MELD-Na) scores were 20.2 and 22.6, respectively.
Two hundred and forty-three patients (27.3%) presented with ACLF at admission: 45 patients (5.1%) had 
ACLF-1, 132 (14.8%) ACLF-2 and 66 (7.4%) ACLF-3.
Clinical characteristics of patients with ACLF at admission or developing it during hospitalization. 
In addition to the 243 patients presenting with ACLF at admission, 57 additional patients (6.3%) developed ACLF 
during hospitalization. Three hundred patients, therefore, had ACLF during the study period, which represents 
a prevalence of 33.7%. Fifty-five patients (6.2%) had ACLF-1, 147 (16.5%) ACLF-2 and 98 (11.0%) had ACLF-3.
Table 1 shows the characteristics of patients with (300) and without (590) ACLF during the study period. Data 
in patients with ACLF were obtained at the time of ACLF diagnosis (at admission or during hospitalization). The 
most common OF in patients with ACLF was liver failure (77.7%), followed by coagulation failure (67.7%), renal 
failure (28.3%), cerebral failure (23.7%), circulatory failure (19%) and respiratory failure (14.3%). The prevalence 
rates of renal and cerebral dysfunction in patients with ACLF were 14.6% and 18.0%, respectively. The prevalence 
of single non-renal organ failure in patients without ACLF was extremely low; liver failure in 7.8%, coagulation 
failure in 9.8%, cerebral failure in 0.5% and circulatory failure in 0.3%. Renal failure by definition is ACLF and no 
patient without ACLF showed respiratory failure. Renal and/or cerebral dysfunctions were also very infrequent 
in patients without ACLF (0.4% and 2.9%, respectively).
Patients with ACLF were younger; more frequently had no prior AD episodes and had been more frequently 
treated with NUCs within the 6 months prior to admission than patients with AD without ACLF. The choice of 
therapy did not impact upon the development of ACLF and, importantly, there was no significant difference in 
the proportion of patients with ACLF receiving the low resistance barrier drug lamivudine compared to the high 
resistance barrier agent entecavir. Bacterial infections, active alcoholism, HBV reactivation and superimposed 
viral infections were more frequent in patients with ACLF than in those without ACLF. In contrast, there was no 
difference in GI-bleeding, hepatotoxic drugs/herbs and surgery between groups. Accordingly, the prevalence of 
1 or more PE was more frequent in patients with ACLF. Patients with ACLF showed higher serum concentration 
of serum aminotransferase and lower mean arterial pressure and serum concentration of sodium than patients 
without ACLF.
White blood cell counts (WCC) were significantly higher in patients with ACLF than in those without ACLF. 
This difference was observed in patients with bacterial infections (5.2 ± 2.6 vs. 12.9 ± 9.9 × 109 cells/l; p < 0.01) as 
well as in patients without bacterial infections (4.7 ± 3.3 vs. 9.7 ± 5.7 × 109 cells/l; p < 0.01). Figure 2A shows that 
there was a close direct relationship between the WCC and the grade of severity of ACLF.
Factors predicting the development of ACLF during hospitalization. Univariate analysis was per-
formed using data obtained at admission in patients without ACLF who did or did not develop ACLF during 
hospitalization (Table 2). Presence of PE’s, bacterial infections and liver failure at admission were significantly 
more frequent, WCC, international normalized ratio (INR), alanineaminotransferase (ALT) and aspartate ami-
notransferase (AST) significantly higher and hematocrit and serum sodium significantly lower in patients devel-
oping ACLF during hospitalization than in those not developing the syndrome. Multivariate analysis disclosed 
leukocyte count (OR = 1.15; 95%CI: 1.08–1.24; p < 0,001), bilirubin (OR = 1.05; 95%CI: 1.02–1.07; p = 0,002), 
INR (OR = 1.66; 95%CI: 1.10–2.51; p = 0,016) and bacterial infection (OR = 3.62; 95%CI: 1.53–8.59; p = 0,004) 
as independent predictors of ACLF during hospitalization. There were no statistically significant differences for 
HBV reactivation and the level of HBV DNA between ACLF and non-ACLF groups in the univariate and multi-
variate analysis.
Mortality. The 28-day and 90-day mortality rates were extremely low (2.6% and 4.6%, respectively) in patients 
without ACLF and very high (44% and 50%, respectively) in patients with ACLF. Following the first six-month 
period, mortality rates did not increase significantly in both groups (Table 1). Figure 2B shows that there was a 
close direct relationship between the severity of ACLF grade at diagnosis and the 28-day and 90-day mortality 
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Characteristics
No ACLF 
(N = 590)
ACLF 
(N = 300) p-value
ACLF grade 
I (N = 55)
ACLF grade 
II (N = 147)
ACLF grade 
III (N = 98) p-value
Age (y) 51.8 ± 10.7 46.5 ± 11.3 < 0.001 49.6 ± 11.3 44.8 ± 11.2 47.1 ± 11.0 < 0.001
Male sex 450(76.3) 233(77.7) 0.641 41(74.6) 119(81.0) 73(74.5) 0.581
Ascites 482(81.7) 229(76.6) 0.072 42(76.4) 115(78.8) 72(73.5) 0.235
Mean arterial pressure (mm Hg) 87 ± 11 84 ± 18 0.011 87 ± 18 87 ± 15 78 ± 21 < 0.001
Cause of cirrhosis 0.002 < 0.001
HBV alone 544(92.3) 263(87.7) 47(85.6) 130(88.5) 86(87.7)
HBV + Alcohol 36(6.1) 19(6.3) 4(7.2) 7(4.7) 8(8.2)
HBV + other hepatitis virus 5(0.8) 12(4.0) 2(3.6) 9(6.1) 1(1.0)
HBV + schistosomiasis 5(0.8) 6(2.0) 2(3.6) 1(0.7) 3(3.1)
HBV-DNA level (IU/ml):
≤ 100 97 (16.4) 60 (20.0) 0.069 7(12.7) 25(17.0) 28(28.6) 0.058
> 100–2 × 104 278 (47.1) 157 (52.3) 30(54.5) 75(51.0) 52(53.1)
> 2 × 104–2 × 106 176 (29.8) 68 (22.7) 13(23.6) 39(26.5) 16(16.3)
> 2 × 106 39 (6.6) 15 (5.0) 5(9.1) 8(5.4) 2(2.0)
HbeAg positve# 194(33.8) 99(35.2) 0.678 14(28.6) 53(36.3% 32(73.2%) 0.556
Treatment with NUCs* 114 (19.3) 95 (31.7) < 0.0001 10(20) 57(37.0) 28(29.2) 0.065
Types of NUCs treatment before enrollment:
Lamivudinealone 67/114 (58.8) 48/95 (50.5) 0.233 4/10(40.0) 30/57(52.6) 14/28(50.0) 0.760
Entecaviralone 16/114 (14.0) 23/95 (24.2) 0.06 4/10 (40.0) 14/57 (24.6) 5/28 (17.9) 0.391
Adefoviralone 15/114 (13.2) 7/95 (7.4) 0.174 2/10 (20.0) 2/57 (3.5) 3/28 (10.7) 0.167
Telbivudinealone 3 /114(2.6) 2 /95(2.1) 0.803 0/10 (0.0) 1/57 (1.8) 1/28 (3.6) 0.703
Tenofoviralone 0 /114(0.0) 0/95 (0.0) 1.000 0/10 (0.0) 0/57 (0.0) 0/28 (0.0) 1.000
≥ 2 NUCs 13/114 (11.4) 15/95 (15.8) 0.354 0/10 (0.0) 10/57 (17.5) 5/28 (17.9) 0.161
Potential precipitating events of ACLF
Bacterial infection*** 35(5.9) 59(19.7) < 0.001 13(23.6) 22(15.1) 24(24.5) < 0.001
Gastrointestinal haemorrhage*** 53(9.0) 23(7.7) 0.507 5(9.1) 6(4.1) 12(12.2) 0.131
Active alcoholism** 36(6.1) 30(10.0) 0.036 4(7.3) 18(12.2) 8(8.2) 0.087
HBV reactivation*** 14(2.4) 27(9.0) < 0.001 5(9.1) 16(10.9) 6(6.1) < 0.001
Superimposed by hepatitis viruses 5(0.8) 9(3.0) 0.031 1(1.8) 7(4.8) 1(1.0) 0.182
Surgery** 7(1.2) 2(0.7) 0.705 0(0.0) 0(0.0) 2(2.0) 0.105
Hepatotoxic drugs or herbs** 8(1.4) 7(2.3) 0.284 1(1.8) 1(0.7) 5(5.1) 0.083
Portal vein thrombosis by CT/
MRI*** 50(8.5) 9(3.0) 0.002 3(5.5) 3(2.0) 3(3.1) 0.486
Precipitating Events(PEs)
No PE 267(45.3) 135(45.0) 0.991 23(41.8) 75(51.0) 37(37.8) 0.253
1 PE 257(43.6) 132(44.0) 25(45.5) 60(40.8) 47(48.0)
> 1 PE 66(11.2) 33(11.0) 7(12.7) 12(8.2) 14(14.3)
Organ failure
Liver failure 46(7.8) 233(77.7) < 0.001 26(47.3) 129(87.8) 78(79.6) < 0.001
Kidney failure 0(0.0) 85(28.3) < 0.001 23(41.8) 16(10.9) 46(47.0) < 0.001
Cerebral failure 3(0.5) 71(23.7) < 0.001 1(1.8) 12(8.2) 58(59.2) < 0.001
Coagulation failure 58(9.8) 203(67.7) < 0.001 4(7.3) 120(81.6) 79(80.6) < 0.001
Circulation failure 2(0.3) 57(19.0) < 0.001 1(1.8) 11(7.5) 45(45.9) < 0.001
Lungs failure 0(0.0) 43(14.3) < 0.001 0(0.0) 6(4.1) 37(37.8) < 0.001
Renal dysfunction 2(0.4) 44(14.6) < 0.001 22(40.7) 14(9.9) 8(8.3) < 0.001
Cerebral dysfunction 17(2.9) 54(18.0) < 0.001 19(34.6) 28(19.1) 10(10.2) < 0.001
Laboratory data
Hematocrit (%) 30 ± 7 30 ± 8 0.876 29 ± 8 31 ± 8 29 ± 8 0.218
Platelet count (× 109/L) 73 ± 56 85 ± 63 0.007 92 ± 79 80 ± 56 88 ± 64 0.020
Serum bilirubin (mg/dL) 5.1 ± 8.5 26.5 ± 16.3 < 0.001 18.2 ± 17.8 29.4 ± 14.6 26.9 ± 16.2 < 0.001
International normalized ratio 1.6 ± 0.6 3.2 ± 2.1 < 0.001 1.8 ± 0.4 3.5 ± 2.6 3.5 ± 1.4 < 0.001
Alanine aminotransferase (U/L) 75 ± 203 315 ± 589 < 0.001 162 ± 281 327 ± 563 385 ± 730 < 0.001
Aspartate aminotransferase (U/L) 88 ± 174 254 ± 451 < 0.001 117 ± 103 292 ± 530 274 ± 430 < 0.001
γ -Glutamyltransferase (U/L) 61 ± 71 70 ± 98 0.159 70 ± 99 70 ± 103 69 ± 89 0.491
Serum creatinine (mg/dL) 0.8 ± 0.2 1.5 ± 1.5 < 0.001 1.9 ± 2.2 1.2 ± 1.1 1.9 ± 1.4 < 0.001
Serum sodium (mmol/L) 136 ± 9 130 ± 7.5 < 0.001 132 ± 6.2 130 ± 7 129 ± 9 < 0.001
Continued
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rates in patients with ACLF. The probability of death in patients with and without ACLF increased with the 
white-cell count (Fig. 3). However, for any given value of white-cell count, the expected death rate was signifi-
cantly higher in ACLF patients. In total, 177 patients died at 90 days. The main cause of death was ACLF (125, 
70.7%), followed by hypovolemic shock (24, 13.5%), septic shock (24, 13.5%) and other/unknown (4, 2.3%).
The CLIF-C ACLF score (Fig. 4, Panel A) and the CLIF-C AD score (Fig. 4, Panel B) were significantly more 
accurate than the MELD and MELD-Na scores in predicting short term and long term mortality in patients with 
and without ACLF, respectively.
To assess whether specific prognostic scores for patients with HBV associated cirrhosis could increase the 
accuracy of CLIF-C ADs and CLIF-C ACLFs, two new scoring systems, the HBV-ACLFs and the HBV-ADs, were 
developed based on the best predictors of survival in our patients with and without ACLF. In univariate analyses 
age, white-cell count and creatinine were found to be significantly associated with 28-day mortality in ACLF 
patients, while age, bilirubin, white-cell count, INR, creatinine and serum sodium significantly predicted 1-year 
mortality in non-ACLF patients. The derived score coefficients were based on the best sub-sets of predictors 
selected in the corresponding survival models:
HBV-ADs = 0.041 age + 0.270 log (serum bilirubin) + 0.82 log (WCC)
HBV-ACLFs = 0.020 age + 0.256 log (serum creatinine) + 0.709 log (WCC)
Both scores improved the accuracy of MELD and MELD-sodium but not the accuracy of CLIF-C ADs and 
CLIF-C ACLFs (Table 3). In fact, CLIF-C ACLFs was significantly more accurate than the HBV-ACLFs at all main 
end-points.
Differences between ACLF in HBV associated cirrhosis and ACLF in cirrhosis due to other 
etiologies included in the CANONIC study4. Results obtained in the current study in patients with 
ACLF associated to HBV infection (HBV-ACLF) were compared to those previously reported by the CANONIC 
Study in patients with ACLF associated with cirrhosis of other etiologies (CANONIC-ACLF) (Table 4). Age was 
significantly lower (46.5 (11.3) vs. 55.8 (11.7); p < 0.001) and male gender significantly more frequent in patients 
with HBV-ACLF, but these features were also observed in patients with AD without ACLF (data not shown). 
Characteristics
No ACLF 
(N = 590)
ACLF 
(N = 300) p-value
ACLF grade 
I (N = 55)
ACLF grade 
II (N = 147)
ACLF grade 
III (N = 98) p-value
Leukocytecount (× 109/L) 4.7 ± 3.3 10.3 ± 6.8 < 0.001 8.1 ± 5.2 9.5 ± 5.3 12.8 ± 8.7 < 0.001
Previous decompensation 0.002 0.015
 No 243(41.2) 157(52.3) 28(50.9) 80(54.4) 49(50.0)
 Yes 347(58.8) 143(47.7) 27(49.1) 67(45.6) 49(50.0)
Mortality(LT-free)
 28 days 15(2.6) 132(44.0) < 0.001 13(23.6) 60(40.8) 59(60.2) < 0.001
 90 days 27(4.6) 150(50.0) < 0.001 19(34.6) 69(46.9) 62(63.3) < 0.001
 180 days 34(5.8) 153(51.0) < 0.001 19(34.6) 70(47.6) 64(63.3) < 0.001
 365 days 49(8.3) 155(51.7) < 0.001 21(38.2) 70(47.6) 64(63.3) < 0.001
Table 1. Characteristics and mortality of patients with and without ACLF during the study period 
(admission plus hospitalization). *within 6 months prior admission; **within 3months prior admission; ***at 
admission; #35 patients (19 patients had ACLF) didn’t have HbeAg test.
Figure 2. (A) Relationship between the severity of ACLF and the WCC.(B) Mortality rate at 28 days and 90 
days according to the grade of ACLF.
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The prevalence of liver failure and coagulation failure was significantly higher and the prevalence of renal failure 
was significantly lower in HBV-ACLF. There were no differences in the prevalence of other OFs between groups. 
Characteristics
Patients not developing 
ACLF N = 590
Patients developing 
ACLF N = 57 p-value
Age (y) 51.8 ± 10.7 51.8 ± 8.8 0.983
Male sex 450(76.3) 43(75.4) 0.888
Ascites* 482(81.7) 46(82.1) 0.994
Mean arterial pressure (mm Hg) 87 ± 11 85 ± 11 0.245
Cause of cirrhosis 0.025
HBV alone 544(92.8) 48(85.7)
HBV + Alcohol 36(6.1) 5(8.9)
HBV + other hepatitis virus 1(0.2) 0(0.0)
HBV + schistosomiasis 5(0.9) 3(5.4)
HBV-DNA level (IU/ml): 0.326
≤ 100 97(16.4) 12(21.1)
> 100–2 × 104 278(47.1) 30(52.6)
> 2 × 104–2 × 106 176(29.8) 14(24.6)
> 2 × 106 39(6.6) 1(1.8)
Potential precipitating events of ACLF
Bacterial infection 35(5.9) 11(19.6) < 0.001
Gastrointestinal haemorrhage 53(9.0) 7(12.3) 0.412
Active alcoholism** 36(6.1) 7(12.3) 0.074
HBV reactivation 14(2.4) 1(1.8) 0.767
Superimposed by hepatitis viruses 5(0.8) 0(0.0) < 0.001
Portal vein thrombosis by CT/MRI on admission* 50(8.5) 3(5.3) 0.554
Surgery** 7(1.2) 0(0.0) < 0.001
Hepatotoxic drugs or herbs** 8(1.4) 0(0.0) < 0.001
Physiological exhaustion** 6(1.0) 3(5.3) 0.043
Precipitating Events(PEs)
 No PE 267(45.3) 16(28.1) 0.043
 1 PE 257(43.6) 32(56.1)
 > 1 PE 66(11.2) 9(15.8)
Organ failures
Liver 46(7.8) 23(40.4) < 0.001
Kidney 0(0.0) 0(0.0) –
Cerebral 3(0.5) 0(0.0) 0.589
Coagulation 58(9.8) 6(10.5) 0.867
Circulation 2(0.3) 1(1.8) 0.133
Lungs 0(0.0) 0(0.0) –
Renal dysfunction 2(0.4) 1(1.9) 0.605
Cerebral dysfunction 17(2.9) 4(7.0) 0.092
Laboratory data
Hematocrit (%) 30 ± 7 27 ± 6 0.001
Platelet count (× 109/L) 73 ± 56 87 ± 59 0.069
Serum bilirubin (mg/dL) 5.1 ± 8.5 14.5 ±  ± 14.2 < 0.001
International normalized ratio 1.6 ± 0.6 1.9 ± 0.6 < 0.001
Alanine aminotransferase (U/L) 75 ± 203 134 ± 211 0.043
Aspartate aminotransferase (U/L) 88 ± 174 153 ± 195 0.011
γ -Glutamyltransferase (U/L) 61 ± 71 57 ± 77 0.751
Serum creatinine (mg/dL) 0.8 ± 0.2 0.8 ± 0.3 0.054
Serum sodium (mmol/L) 136 ± 9 129 ± 8 < 0.001
Leukocyte count (× 109/L) 4.7 ± 3.3 8.6 ± 4.7 < 0.001
Previous decompensation 0.696
 No 243(41.2) 25(43.9)
 Yes 347(58.8) 32(56.1)
Table 2. Univariate analysis of ACLF development during hospitalization in patients without ACLF at 
admission. *at admission; **within 3 months prior hospitalization.
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Accordingly, liver function tests (serum bilirubin, ALT and AST, and INR) were significantly worse in patients 
with HBV-ACLF infection while serum creatinine, gamma-glutamyltranferase and serum sodium, were signifi-
cantly higher in patients with CANONIC-ACLF. There were no differences in WCC between groups. Importantly, 
the incidence of a prior history of AD was significantly lower in patients with HBV-ACLF indicating that a higher 
proportion of patients developed ACLF at the same time as the first AD of cirrhosis.
The prevalence of ACLF-1 was significantly higher in CANONIC-ACLF. In contrast, the prevalence of 
ACLF-2 and ACLF-3 was significantly more frequent in patients with HBV-ACLF. Accordingly, the 28-day and 
90-day mortality was significantly higher in patients with HBV-ACLF.
Discussion
The results of this study validate the diagnostic ability of CLIF-C OFs to differentiate hospitalized HBV patients 
with decompensated cirrhosis into those with ACLF and those without. As observed in the CANONIC study4, 
the 28-day mortality rate for our patients without ACLF was very low (2.6%) compared with a 44% mortality in 
those classified as ACLF. Moreover, the data demonstrated the significance of OFs in determining survival in this 
HBV population; mortality rates increased progressively with the number of OFs. The CLIF-C ACLF and the 
CLIF-C AD scores performed better at predicting prognosis than MELD and MELD-Na scores3,5. Specific score 
developed from the data of patients with HBV associated ACLF (HBV-ACLFs) was less accurate than the previ-
ously defined CLIF-C ACLF score in predicting outcome. From the pathophysiological perspective, the putative 
importance of inflammation in the pathogenesis of ACLF was confirmed in the HBV population, as white cell 
count correlated with the presence and grade of ACLF and remained an independent predictor of mortality4. 
Taken together, the data suggest that the CLIF Consortium criteria for the diagnosis and prognosis of hospitalized 
cirrhotic patients that was developed in Europe in non-HBV patients can also be used in Chinese patients with 
HBV infection with a high degree of accuracy.
Despite the many similarities in the diagnostic and prognostic criteria for ACLF in HBV patients with the 
CANONIC cohort, important differences were observed in the Chinese cohort with HBV compared with the 
European non-HBV patients suggesting that ACLF due to hepatitis B confers unique characteristics to the 
syndrome.
One of the most intriguing observations was the main organ failures in HBV cohort was ‘Liver’ and 
‘Coagulation’, which tended to occur together and more frequently (78.7 and 68.4% respectively) accounting for 
ACLF gradation of ACLF-2. As the proportion of patients with ACLF-2 was over represented while the propor-
tion of patients in the ACLF-1 cohort was low in the HBV population, the 28-days mortality of the HBV cohort 
was significantly higher than that observed in the non-HBV, CANONIC cohort (43% vs. 30%)4. A possible expla-
nation for the observation of increased ‘Liver’ and ‘Coagulation’ failure is likely to be the pathological character-
istics of HBV ACLF patients. Our previous study10 explored that submassive hepatic necrosis accompanied with 
cholestasis and/or ductular bilirubinostasis (sepsis) were the major hepatic pathological features of HBV related 
ACLF patients in contrast to mainly inflammation and bilirubinostasis in the alcohol related ACLF patients11,12. 
Lacking prothrombin biosynthesis caused by extensive parenchymal hepatocyte destruction and severe cholesta-
sis around residual cirrhotic nodules in HBV submassive hepatic necrosis liver are, therefore, reasonable expla-
nations for prolonged INR and hyperbilirubinemia. For precipitating events, more than 80% patients were not 
receiving NUC’s and therefore, it was not surprising to note that they had detectable levels of HBV DNA at the 
time of hospital admission but surprisingly, less than 5% patients showed clinical and virological evidence of HBV 
reactivation13. There was no significant difference in the distribution of HBV-DNA levels in patients who did, 
or did not, develop ACLF suggesting that HBV associated hepatitis was not related to the development of liver 
dysfunction14,15. However it is well established that changes in HBV-DNA may precede liver injury and given that 
the transaminase levels were increased in patients with ACLF compared to those who did not develop ACLF it is 
impossible to exclude an effect of HBV. As no other precipitating event was detected in about 60% of the patients, 
it is possible that there may well have been ‘HBV flares’ accounting for the development of ACLF but this hypoth-
esis will need to be studied further16,17. It was also notable that other risk factors for ACLF such as infection with 
Figure 3. Relationship between the expected probability of death at 28-days, the presence or the absence of 
ACLF and the white cell count. 
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other hepatitis viruses were over represented in those HBV patients that developed ACLF. Not surprisingly, alco-
hol abuse on the background of HBV cirrhosis was also associated with the occurrence of ACLF more frequently. 
As in the CANONIC cohort, the clinical course of ACLF and the associated mortality were not related to the 
presence and type of precipitating events. This indicates that, although precipitating events are important in the 
Figure 4. Panel (A): Accuracy of the CLIF-C ACLFs (red line) as compared to MELDs (green) and MELD-Nas 
(orange) in predicting 28-day and 90-day mortality of patients with ACLF associated to cirrhosis due to HBV 
infection. Comparison of the areas under the ROC curves (AUROCs) estimated for each score. The CLIF-C 
ACLFs showed a significantly higher predictive ability in comparison with the MELDs and MELD-Nas scores 
for both the 28-day and 90-day mortality. Panel (B): Accuracy of the CLIF-C ADs (red line) as compared to 
MELDs (green) and MELD-Nas (orange) in predicting 6-month and 1-year mortality of patients with AD 
(without ACLD) due to HBV associated cirrhosis. Comparison of the AUROCs estimated for each score. The 
CLIF-C ADs showed significantly higher predictive ability in comparison to the MELDs.
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development of ACLF, once it develops the clinical course and mortality depend more on the severity of systemic 
inflammation and number of OFs.
Another interesting observation was that, in contrast to the CANONIC study, which comprised non-HBV 
patients, kidney failure rate in the HBV patients was significantly lower (52% vs. 28.6%). The mechanism of 
lower rates of renal failure in the HBV ACLF population is not clear but may suggest different mechanisms of 
injury. In the alcoholic cirrhosis population, which formed the majority of patients in the CANONIC study, gut 
bacterial translocation is pathophysiologically important and has been shown to possibly ‘prime’ the kidneys by 
up-regulation of toll-like receptor 4 to the effect of a superimposed inflammatory insult18–20. Alternatively, or in 
addition, this difference may reflect that a ‘hepatic’ insult such as HBV flares/reactivation compared with ‘extrahe-
patic’ insult such as bacterial infection or alcohol abuse, which were the predominant precipitating illnesses in the 
CANONIC cohort4, was an important mechanism of ACLF in our series. It is therefore, interesting to note that in 
HBV patients with infections or alcoholism as the precipitating event, the rate of renal failure was 19.6%, (30/153 
patients), which was significantly higher than in patients without these PE’s (7.5% (55/737) patients) (P < 0.001).
It is also interesting to note that white cell count was an independent predictor of mortality in both the cohorts 
indicating the strong and the very important influence of inflammation in driving the pathogenesis of HBV 
related ACLF, as was the case in the CANONIC patients. As illustrated in Fig. 2A, the white cell count was signif-
icantly higher in all the ACLF cohorts and increased progressively with more severe grades of ACLF. Remarkably, 
the presence of bacterial infection at each stage of ACLF was associated with markedly higher WCC count, which 
was absent in the non-ACLF cohort. Moreover, as illustrated in Fig.3, the correlation between leucocyte count 
and 28-day mortality showed that for any given value of white-cell count and (presumably) inflammation, the 
probability of death was significantly higher in patients with ACLF than in those without the syndrome. Bacterial 
infection as a precipitating event was significantly more commonly associated with ACLF and its presence was 
associated with more severe grades of ACLF in this HBV cohort as was the case with the CANONIC patients4. 
These observations, which confirm the results from the CANONIC study, suggest that in addition to systemic 
inflammation, altered host response to injury accounts for organ failure even in the HBV patients who develop 
ACLF1. Further studies are needed to define the underlying mechanisms.
HBV patients with ACLF were significantly younger than patients in the European cohort but in both cohorts, 
the ACLF patients were younger than the patients with AD. Severity of ACLF also correlated inversely with age. 
Additionally, 52.3% patients with HBV related ACLF had no previous history of decompensation, a proportion 
that was significantly higher than in patients with HBV infections without ACLF. Taken together, the data show 
clearly that HBV-ACLF is pathophysiologically similar to the CANONIC patients as in both cohorts ACLF was 
more commonly associated with younger age, lack of previous decompensation and inflammation21,22.
The CLIF-C ACLF score was developed to provide sequential prognostic information in ACLF patients in 
the non-HBV cohort and validated independently in a similar population3. Its performance in predicting mor-
tality was shown to be of similar accuracy in the HBV-ACLF patients. Importantly, its performance was signifi-
cantly better than the best scoring systems that are currently used to allocate organs for liver transplantation, the 
MELD23 and the MELD-Na21 scores providing a further independent validation of the CLIF-C ACLF score for 
HBV-ACLF patients. Using the dataset, a bespoke scoring system for the HBV ACLF patients, the HBV-ACLF 
score was developed. It is important to note that the performance of this etiology specific scoring system was 
significantly less accurate compared with the CLIF-C ACLF score confirming that this score is not be constrained 
by etiology. As the 1-year mortality rate was extremely low in the non-ACLF patients (49 patients; 8.3%), assess-
ment of the CLIF-C AD score as a prognostic model for the non-ACLF patients5 is likely to be underpowered 
and therefore the data should be interpreted with caution. Nevertheless, the data show that the score performs 
C-index
28 days P 90 days P 180 days P 360 days p
Patients with ACLF in the whole study
HBV-ACLFs 0.654  (0.604–0.705)
0.645  
(0.596–0.694)
0.644  
(0.595–0.693)
0.640  
(0.591–0.688)
CLIF-C ACLFs 0.704  (0.661–0.748) 0.023
0.685  
(0.643–0.727) 0.057
0.687  
(0.645–0.728) 0.041
0.682  
(0.640–0.723) 0.046
MELDs 0.554  (0.497–0.610) < 0.001
0.543  
(0.490–0.596) < 0.001
0.543  
(0.491–0.595) < 0.001
0.540  
(0.488–0.591) < 0.001
MELD-Nas 0.549  (0.493–0.605) < 0.001
0.541  
(0.488–0.594) < 0.001
0.541  
(0.488–0.594) < 0.001
0.537  
(0.486–0.589) < 0.001
Patients without ACLF in the whole study
HBV-ADs 0.737  (0.659–0.814)
0.716  
(0.650–0.781)
0.720  
(0.659–0.782)
0.721  
(0.666–0.775)
CLIF-C ADs 0.733  (0.662–0.803) 0.92
0.724  
(0.663–0.784) 0.796
0.728  
(0.671–0.784) 0.783
0.728  
(0.677–0.779) 0.788
MELDs 0.667  (0.575–0.759) 0.08
0.653  
(0.580–0.725) 0.056
0.657  
(0.589–0.724) 0.042
0.639  
(0.577–0.700) 0.003
MELD-Nas 0.719  (0.643–0.796) 0.653
0.710  
(0.646–0.773) 0.886
0.701  
(0.640–0.762) 0.54
0.682  
(0.626–0.738) 0.164
Table 3. HBV-ACLFs and HBV-ADs comparing with c-index of CLIF-C ACLFs and CLIF-C ADs and with 
MELDs andMELD-Nas.
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significantly better than the MELD score at all the time points and does not significantly improve the perfor-
mance of MELD-Na score. A bespoke HBV scoring system for the non-ACLF HBV cohort was developed from 
the data. Its performance was shown to be similar to that of CLIF-C AD score confirming its validity in the HBV 
non-ACLF population.
Characteristics
Chinese Patients 
N = 300
CANONIC patients 
N = 417 p-value
Age (y) 46.5 ± 11.3 55.8 ± 11.7 < 0.001
Male sex 233(77.7) 267(64.0) < 0.001
Previous decompensation < 0.001
No 157(52.3) 98(24.9)
Yes 143(47.7) 295(75.1)
Ascites 229(76.6) 324(78.5) 0.7346
Mean arterial pressure(mmHg) 84 ± 18 81 ± 13 0.0142
Cause of cirrhosis
Alcohol,noHCV – 233(58.4) –
No Alcohol,HCV – 59(14.8) –
Alcohol+ HCV – 37(9.3) –
Other Etiologies* – 70(17.5) –
HBV alone 263(87.7) – –
HBV+ Alcohol 19(6.3) – –
HBV+ other hepatitis virus 12(4.0) – –
HBV+ schistosomiasis 6(2.0) – –
Organ failures
Liver 233(77.7) 157(37.7) < 0.001
Kidney 85(28.3) 217(52.0) < 0.001
Cerebral 71(23.7) 94(22.5) 0.7925
Coagulation 203(67.7) 118(28.3) < 0.001
Circulation 57(19.0) 78(18.7) 0.9977
Lungs 43(14.3) 47(11.3) 0.2684
Renal dysfunction 44(14.7) 64(15.4) 0.801
Cerebral dysfunction 54(18.0) 130(31.3) < 0.001
Laboratory data
Hematocrit(%) 30 ± 8 28 ± 9 0.0018
Leucocytes(× 109/L) 10.3 ± 6.8 9.5 ± 6.0 0.1033
Platelet count(× 109/L) 85 ± 63 103 ± 70 < 0.001
Serum bilirubin(mg/dL) 27 ± 16 11 ± 11 < 0.001
International normalized ratio 3.2 ± 2.1 2.0 ± 0.8 < 0.001
Alanine aminotransferase(U/L) 315 ± 589 69 ± 122 < 0.001
Aspartate aminotransferase(U/L) 254 ± 451 202 ± 991 0.3454
γ -Glutamyltransferase(U/L) 70 ± 98 154 ± 207 < 0.001
Serum creatinine(mg/dL) 1.5 ± 1.5 2.0 ± 1.5 < 0.001
Serum sodium(mmol/L) 130 ± 7 133.5 ± 7 < 0.001
Site of hospitalization < 0.001
Intensive care unit 0(0.0) 98(23.6)
Ward 300(100.0) 318(76.4)
ACLF grades: < 0.001
ACLF-I 55(18.3) 214(51.3)
ACLF-II 147(49.0) 147(35.3)
ACLF-III 98(32.7) 56(13.4)
Mortality
28 days 129(43.0) 125(30.0) < 0.001
90 days 151(50.3) 178(42.7) 0.0624
180 days 154(51.3) 204(48.9) 0.6358
365 days 156(52.0) 228(54.7) 0.4709
Table 4. Differences of clinical characteristics between patients with ACLF included in the current 
study and patients from the CANONIC study. *Hepatitis B-associated cirrhosis in 21 patients (5.2%). The 
CANONIC data is reproduced with permission from Moreau et al. Gastro2013.
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There are two further points that should be emphasized. Firstly, NUCs were not covered by nation wide 
medical insurance in China before 2009, the persistence of antiviral therapy for HBV was paid by the patient’s 
themselves. This can explain the reason why only a low percentage of enrolled patients (23.5%) were treated 
by NUCs before enrollment (patients’ data collected between 2005 and 2010). Secondly, a recent study24 from 
another HBV high endemic region in China has reported the rate of both flare-up and exacerbation of HBV were 
35.8% in ACLF patients, while our HBV reactivation rate was 9.0%. Different definition about HBV reactivation 
and flare-up/exacerbation caused the significant gap in these two studies. HBV reactivation was defined as both 
ALT > 3NL and HBV-DNA > 100 U/L due to NUC resistance and cessation of the antiviral treatment in current 
study. However, In the study by Shi Y et al.’s study HBV ‘flare-up’ was defined as more than twice of the baseline 
value with HBV DNA positive within one month before admission and ‘exacerbation’ defined as ALT > 5NL with 
HBV DNA positive24.
There are still lack of clarity amongst Asian hepatologists in understanding whether acute decompensation 
(AD) of cirrhotic patients is related to precipitating factors or disease complications. In current study, 52% of 
HBV ACLF patients had new occurrence of decompensation (Table 4) which reflects that a precipitating event is 
the cause of AD in more than half the ACLF patients.
In current study multiple organ failure cirrhotic patients may include some chronic liver failure patients, 
However the liver specific multiple organ failure score (CLIF-OF) has clearly demonstrated that it can distinguish 
high mortality from low mortality patients not only in Eastern type (HBV) but also in Western type (Alcoholic) 
cirrhotic AD patients. This is the key point of this study to exhibit that a uniform diagnostic criterion could be 
applied for distinguishing ACLF from both HBV and alcoholic cirrhotic AD patients.
The study may be criticized because of its retrospective nature and the lack of a head to head comparative 
population with a non-HBV cohort. Nonetheless, because this study was based in a single hospital with access to 
all the patient records and biochemistry, there were very few missing data making the observations robust and 
increasing the validity of conclusions. Another potential criticism of this study is the management of the patients 
in a ward-based rather than ICU environment. It is possible that this may affect the results of the analysis but 
the similarities to the outcomes obtained and observations made in the CANONIC study, makes this is unlikely. 
Other groups have shown that the CLIF sequential organ failure assessment score (SOFA), which was first used in 
the CANONIC study to define ACLF, can be used to accurately classify patients further confirming the fidelity of 
the data and the validity of the observations from the present study25–31.
In summary, although ACLF in HBV patients (present study) and in patients with mainly alcohol related or 
hepatitis C virus (CANONIC study) exhibited differences in clinical features, the data in this study demonstrates 
that ACLF is a clinically and pathophysiologically distinct entity independent of the underlying etiology. First, 
age, previous decompensations and the presence or type of precipitating events were similar in the disease course 
and prognosis in both populations. Second, a systemic inflammatory (white cell count) response independently 
correlated with the presence and grade of ACLF and was an independent predictor of mortality. Third, the liver 
specific multiple organ failure score (CLIF-C OFs) had the equal diagnostic ability to differentiate ACLF from 
AD patients and the number of OFs determined short term mortality of the patients. Finally, the prognostic score 
designed in a non-HBV cohort was equally accurate for patients with HBV and could not be improved signifi-
cantly increased by a bespoke disease specific score.
In conclusion, ACLF is by far the most frequent cause of death in patients with acute decompensation due 
to HBV infection, significantly more frequent than in patients with alcoholic and/or HCV infection. The data 
presented here confirm the validity of the CLIF criteria in the diagnosis and prognosis of patients with ACLF. The 
study also identified key clinical differences that should be the subject of future studies.
Methods
Study and patients characteristics. The study consisted in a retrospective analysis of 890 patients admit-
ted to Ren Ji Hospital, Shanghai Jiao Tong University, from January 2005–December 2010 from a total of 3004 
patients admitted to the hospital (Supplementary table S1). Patients with chronic hepatitis B virus infection and 
cirrhosis (hepatitis B surface antigen (HBsAg) + ve and antibody to hepatitis B core antigen (anti-HBc) + ve in 
the absence of other potential cause of cirrhosis; chronicity was defined by the presence of HBsAg + ve for > 6 
months) who had either ascites, hepatic encephalopathy, variceal hemorrhage and/or bacterial infections, or other 
clinical, ultrasonography and/or laboratory data compatible with the diagnosis of cirrhosis were recruited in the 
analysis. The criterion of bacterial infection in current study was the same as CANONIC Study4 and included 
spontaneous bacterial peritonitis, spontaneous bacteremia (positive blood culture), urinary tract infection, pneu-
monia and cellulitis. Two hundred and sixty-four patients received an orthotopic (87%) or living donor (13%) 
liver transplant (LT) within 90-days following admission and in 95% of these patients the presence of cirrhosis 
was confirmed by liver histology. Thirteen patients had advanced fibrosis histologically. Informed consent had 
been obtained from all patients and/or their relatives about usage of their clinical and pathological data. The eth-
ics committee of the Ren Ji Hospital approved the study and methods (Ethics Number EC (2014) 148K). Methods 
were carried out in accordance with the approved guidelines.
Data collection. Data collection was performed in December 2013. Demographic data, prior history of a 
decompensation, main cause of admission, precipitating events (PE) associated with the acute decompensation 
or ACLF, other clinical and exploratory data, laboratory tests, mean arterial pressure, pulse oximetry, markers of 
HBV infection, and antiviral treatment given within 6-months prior to and during hospitalization were obtained 
from patient medical records or the hospital database. Clinical and laboratory data given in the article are those 
obtained at the time of admission into the hospital or, when indicated, at the time of diagnosis of ACLF. Survival 
rates at 28-days, 90-days, 6-months and 1-year following enrollment were obtained through patient medical 
records or by direct contact with the patients or their families.
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Diagnostic criteria for ‘reactivation’ of HBV infection. Reactivation of hepatitis B32–34 was diagnosed 
if patients presented with at least one of the following criteria:
1. Absolute increase in both HBV-DNA (> 1000 copies/ml; [> 200 IU/ml]) and ALT > 3 times normal in a pa-
tient on continuous treatment with nucleotide analogs (NUCs) due to the development of NUC resistance 
OR
2. An acute increase in HBV-DNA and ALT in a patient on continuous treatment with NUCs following cessa-
tion of the antiviral treatment OR
3. Acute increase in ALT associated with HBsAg reappearance in 2 consecutive tests 5 days apart and increase 
in HBV-DNA (> 105 copies/ml; [> 2 × 104 IU/ml]) in a patient with prior negative HBsAg and positive 
anti-HBc antibody.
Diagnostic criteria of ACLF and prognostic scores. Definitions, diagnostic criteria and methodol-
ogy used to analyze the study data were those proposed by the investigators of the CLIF Consortium in the 
CANONIC Study3 (Supplementary Figure S2). The term ACLF defines a syndrome characterized by AD of cir-
rhosis associated to organ failure (OF) and poor short-term probability of survival3,5. CLIF-C OFs was used for 
the diagnosis of organ failures (liver failure: serum bilirubin ≥ 12 mg/dl; renal failure: serum creatinine ≥ 2 mg/dl 
or renal support therapy; cerebral failure: grade III-IV hepatic encephalopathy; coagulation failure: INR ≥ 2.5; 
respiratory failure: PaO2/FiO2 ≤ 200 or SpO2/FiO2 ≤ 214; circulatory failure: vasoconstrictor requirements to 
maintain arterial pressure). In addition to organ failure, renal dysfunction (as defined by a serum creatinine of 
1.5–1.9 mg/dl) and/or cerebral dysfunction (grade 1–2 hepatic encephalopathy) were also used for the diagnosis 
of ACLF in patients with single non-renal organ failure. (Supplementary Figure S2).
Based on the presence of organ failure and renal and/or cerebral dysfunction the following groups of patients 
were either excluded or included from the diagnosis of ACLF: 1. Excluded: (a) No organ failure; (b) Single 
non-renal organ failure without renal and/or cerebral dysfunction. Included: (A) Single renal failure (ACLF grade 
I, ACLF-1); (B) Single non-renal organ failure plus renal dysfunction and/or cerebral dysfunction (ACLF-1); (C) 
2 organ failures (ACLF-2); (D) 3–6 OFs (ACLF-3)4.
CLIF-C ACLF score (based on CLIF-C OF score plus age and white blood cell count, WCC), CLIF-C AD score 
(based on serum creatinine, INR, serum sodium, age and WCC) were used to assess risk of mortality in patients 
with ACLF and AD3,5, respectively and compared to MELD23, and MELD-Sodium (MELD-Na) scores21.
An online application to compute CLIF Consortium scores and estimate the correspondingpredicteddeath 
rate at time ‘t’ is available at the CLIF-Consortium website: http://www.clifconsortium.com/.
Statistics. All the data was analyzed at the Data Management Centre of the CLIF Consortium, Barcelona in 
line with the analysis of the previously published CANONIC study. All the variables used in statistical analysis 
were obtained at the time of hospital admission or, when indicated, at the time of diagnosis of ACLF. Data are 
presented as mean ± standard deviation for continuous parameters or frequencies and percentages for categor-
ical variables. Mortality rates were estimated as transplant-free (patients who received a liver transplant were 
considered as lost to follow-up). Univariate analysis using Chi-square, Student’s t test or one way analysis of 
variance were performed to assess differences between groups or the association between all potential factors 
and outcomes. Two specific scores for HBV patients with and without ACLF (HBV-ACLF and HBV-AD scores) 
were estimated by fitting two Cox proportional-hazards models for 28-day and 1-year mortality, respectively. The 
initial model included all the risk factors found to be significantly associated with mortality in univariate anal-
yses. Each score coefficients were based on the best independent sub-sets of predictors selected by means of the 
stepwise-forward method based on changes in model Likelihood Ratio (p-in = p-out = 0.05).
Harrell’s concordance index (C-index) was used to assess the discrimination ability of each severity score35.
Statistical comparison of C-index estimates was carried out for the main study time-points using the stand-
ardized normal approximation. A confirmatory analysis was carried out to assess the discrimination ability of 
the prognostic scores by estimating and comparing the corresponding Areas under the ROC curves (AUROCs). 
A univariate analysis was also carried out to identify the main baseline factors associated to the development of 
ACLF during the hospitalization in patients without ACLF at admission. A Logistic Regression model was fitted 
including all the significant potential predictors from this analysis. The best independent predictors of ACLF 
development in those without ACLF at presentation was selected by means of the stepwise-forward method based 
on changes in the model Likelihood Ratio (p-in = p-out = 0.05). In all statistical tests, the significance level was 
set at p < 0.05.
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